The Use of Classic Psychedelics for Depressive and Anxiety-Spectrum Disorders: A Comprehensive Review.
Journal of clinical psychopharmacology Vivian Kim, Scott M Wilson, Mary E Woesner 3 citations
Classic psychedelics, which act on serotonin receptors, show promise for treating depression and anxiety disorders according to clinical trials published since 2020. These compounds have been tested for major depressive disorder, treatment-resistant depression, bipolar II, and anxiety-spectrum disorders. However, the evidence is limited by short follow-up periods, nonstandard dosing, and study designs. Many findings come from post hoc analyses of a few parent studies. The review calls for more original research with larger, diverse samples, standardized methods including blinding, and long-term follow-up to assess benefits and adverse effects. Psychological support and the therapeutic alliance are also important considerations.